Article

Associations of DMT therapies with COVID-19 severity in multiple sclerosis

2021-02-10

Abstract excerpt

<h4>Background</h4> People with multiple sclerosis (MS) are a vulnerable group for severe COVID-19, particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS. <h4>Methods</h4> Data from 12 data-sources in 28 countries were aggregated. Demographic and clinical covariates were queried, alongside CO...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 98371bf9-1652-5a0e-86a0-f8f87a2b5dca
DOI: 10.1101/2021.02.08.21251316

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Associations of DMT therapies with COVID-19 severity in multiple sclerosisDOI 10.1101/2021.02.08.21251316Read

Associations of DMT Therapies with COVID-19 Severity in Multiple Sclerosis: An International Cohort StudySemantic proximity Read

Disease Modifying Therapies and COVID-19 Severity in Multiple SclerosisSemantic proximity Read

COVID-19 Severity in Multiple Sclerosis: Putting Data Into ContextSemantic proximity Read

Increased Rate of Hospitalisation for COVID-19 Amongst Rituximab Treated Multiple Sclerosis Patients: A Study of the Swedish MS RegistrySemantic proximity Read

COVID-19 in Multiple Sclerosis Patients and Risk Factors for Severe InfectionSemantic proximity Read

SARS-CoV-2 infection among patients with multiple sclerosis; A cross-sectional studySemantic proximity Read

COVID-19 OUTCOMES IN MS: EARLY EXPERIENCE FROM NYU MULTIPLE SCLEROSIS COMPREHENSIVE CARE CENTERSemantic proximity Read

COVID-19 in multiple sclerosis patients and risk factors for severe infection.Semantic proximity Read

Phenotyping Healthcare Use 2-3 Decades Before the First Multiple Sclerosis Demyelinating Event.Semantic proximity Read

Impact of mass vaccination on SARS-CoV-2 infections among the total multiple sclerosis population receiving immunomodulatory disease-modifying therapies in EnglandSemantic proximity Read

Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platformSemantic proximity Read

The Phenotypes of Multiple Sclerosis Differ Significantly in Relative and Excess Mortality.Semantic proximity Read